

# TaUH patient cohort (FinOMOP)

**First published:** 01/02/2024

**Last updated:** 13/08/2025

Data source

Human

Hospital inpatient records

Hospital outpatient visit records

## Administrative details

### Administrative details

#### Data source ID

1111135

#### Data source acronym

FinOMOP\_Tampere

#### Data holder

[Tampere University Hospital](#)

#### Data source type

Hospital inpatient records

Hospital outpatient visit records

## Care setting

Hospital inpatient care

Hospital outpatient care

---

## Data source qualification

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

---

## Data source website

<https://www.pirha.fi/>

# Contact details

Sampo Kukkurainen [sampo.kukkurainen@pirha.fi](mailto:sampo.kukkurainen@pirha.fi)

Main

[sampo.kukkurainen@pirha.fi](mailto:sampo.kukkurainen@pirha.fi)

Leena Hakkarainen [leena.hakkarainen@pirha.fi](mailto:leena.hakkarainen@pirha.fi)

Alternate

[leena.hakkarainen@pirha.fi](mailto:leena.hakkarainen@pirha.fi)

# Data source regions and languages

## Data source countries

Finland

---

## Data source languages

Finnish

---

## Data source regions

Pirkanmaa

## Data source establishment

### Data source established

01/05/2007

---

### Data source time span

**First collection:** 15/01/1991

The date when data started to be collected or extracted.

## Publications

### Data source publications

[Maximal surgical effort increases the risk of postoperative complications in the treatment of advanced ovarian cancer](#)

[Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study](#)

[Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center](#)

[Prospective centralized repeated resectability assessment during first-line treatment in 812 Finnish colorectal cancer patients with liver metastases \(subgroup in the RAXO-study NCT01531621\)](#)

## Studies

List of studies that have been conducted using the data source

DARWIN EU® - RR Childhood hypertension and sartans prescribing in children

DARWIN EU® - Feasibility of studies on early (pre-symptomatic) stages of type 1 diabetes mellitus in the DARWIN EU® network

## Data elements collected

### The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

---

#### **Rare diseases**

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.

Yes

---

#### **Pregnancy and/or neonates**

Does the data source collect information on pregnant women and/or neonatal subpopulation (under 28 days of age)?

Yes

---

#### **Hospital admission and/or discharge**

Yes

---

#### **ICU admission**

Is information on intensive care unit admission available?

Yes

---

### **Cause of death**

Not Captured

---

### **Prescriptions of medicines**

Captured

---

### **Prescriptions vocabulary**

ATC

---

### **Dispensing of medicines**

Captured

---

### **Dispensing vocabulary**

ATC

---

### **Advanced therapy medicinal products (ATMP)**

Is information on advanced therapy medicinal products included? A medicinal product for human use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art 1(1)].

Yes

---

### **Contraception**

Is information on the use of any type of contraception (oral, injectable, devices etc.) available?

No

---

### **Indication for use**

Does the data source capture information on the therapeutic indication for the use of medicinal products?

Not Captured

---

### **Medical devices**

Is information on medicinal devices (e.g., pens, syringes, inhalers) available?

No

---

### **Administration of vaccines**

No

---

### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

---

### **Procedures vocabulary**

Other

---

### **Procedures vocabulary, other**

Finnish version of Nomesco

---

### **Healthcare provider**

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available?  
The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

---

### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

---

## Genetic data

Are data related to genotyping, genome sequencing available?

Captured

---

## Genetic data vocabulary

Other

---

## Biomarker data

Does the data source capture biomarker information? The term “biomarker” refers to a broad subcategory of medical signs ( objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

---

## Biomarker data vocabulary

Other

---

## Biomarker vocabulary, other

Kuntaliitto laboratory codes, local laboratory codes

---

## Patient-reported outcomes

Is information on patient-reported outcomes (e.g., quality of life) available?

No

---

## Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

No

---

## Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

---

### **Unique identifier for persons**

Are patients uniquely identified in the data source?

Yes

---

### **Diagnostic codes**

Captured

---

### **Diagnosis / medical event vocabulary**

ICD-10

---

### **Medicinal product information**

Captured

---

### **Medicinal product information collected**

Active ingredient(s)

---

### **Medicinal product vocabulary**

ATC

---

### **Quality of life measurements**

Not Captured

---

### **Lifestyle factors**

Not Captured

---



## **Sociodemographic information**

Captured

---

### **Sociodemographic information collected**

Age

Gender

## Quantitative descriptors

### Population Qualitative Data

#### **Population age groups**

Paediatric Population (< 18 years)

Neonate

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly ( $\geq$  65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Estimated percentage of the population covered by the data source in the catchment area**

100%. All inhabitants of the region are entitled to public healthcare, specialized and emergency health care. Catchment population for secondary care is 540 000 and for tertiary care 920 000.

---

### **Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)**

In the patient registry of the Tampere University Hospital since 2007, there are a total of 954,294 electronic medical records, of which 854,014 patients are still alive. Very few people use only private services.

## Population

### **Population size**

954294

---

### **Active population size**

854014

## Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	237546	237026
Term newborn infants (0 – 27 days)	100711	100571

Age group	Population size	Active population size
Infants and toddlers (28 days - 23 months)	22145	22056
Children (2 to < 12 years)	69947	69792
Adolescents (12 to < 18 years)	44743	44607
Adults (18 to < 46 years)	284357	280787
Adults (46 to < 65 years)	175759	161950
Elderly ( $\geq$ 65 years)	256632	174251
Adults (65 to < 75 years)	107416	88197
Adults (75 to < 85 years)	92274	63345
Adults (85 years and over)	56942	22709

## Median observation time

**Median time (years) between first and last available records for unique individuals captured in the data source**

2.79

**Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt**

2.74

## Data flows and management

### Access and validation

## Governance details

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

### FinOMOP\_data\_governance

English (696.7 KB - PPTX)

[View document](#)

## Biospecimen access

Are biospecimens available in the data source (e.g., tissue samples)?

Yes

## Biospecimen access conditions

We are in close collaboration with the Finnish Clinical Biobank Tampere (FCBT). Finnish biobanks have their own permit application process (<https://site.fingenious.fi/en/>).

FCBT can collect all kinds of biospecimen in different phases of the treatment based on patients' consent (100,000 active consents). Ready to go samples: 50,000 DNA, serum, and plasma samples; hundreds of fresh frozen tumor samples; hundreds of SCF-samples, and 3,4M FFPE samples.

## Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

## Description of data collection

All patients who visit the hospital are recorded in our IT system (Oberon). The hospital has been completely paperless since 2010. After that all visits, all procedures and given treatments have been recorded systematically in the electronic format. We use more than hundred different operational IT systems. For secondary use, the individual level data is pooled into a data lake. Data relevant for research is then collected through an ETL-process into a single research SQL data base. The OMOP mapping and ETL processes are built in collaboration with the FinOMOP Consortium; other Finnish University Hospitals and the Institute of Health and Wellbeing.

## Event triggering registration

### Event triggering registration of a person in the data source

Birth

Start of treatment

---

### Event triggering de-registration of a person in the data source

Death

---

### Event triggering creation of a record in the data source

first event

## Data source linkage

### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

# Linked data sources

## Pre linked

Is the data source described created by the linkage of other data sources?

No

---

## Data source, other

Data from many nation-wide health registries such as drug purchase, visual impairment, cancer, retirement due to a disease registries and many others, can be combined to the Tampere University Hospital patient registry. The combination needs a specific research plan and data permit.

---

## Linkage strategy

Combination

---

## Linkage variable

social security number

---

## Linkage completeness

High completeness

---

# Data management specifications that apply for the data source

## Data source refresh

Monthly

---

## Informed consent for use of data for research

Not Required

---

## Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

Yes

---

## Data source preservation

Are records preserved in the data source indefinitely?

Yes

---

## Approval for publication

Is an approval needed for publishing the results of a study using the data source?

Yes

---

## Data source last refresh

25/07/2025

# Common Data Model (CDM) mapping

## CDM mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

## CDM Mappings

### CDM name

OMOP

---

**CDM website**

<https://www.ohdsi.org/Data-standardization/>

---

**Data source ETL CDM version**

5.4

---

**Data source ETL frequency**

6,00 months

---

**Data source ETL status**

Completed